News

19.12.2018 / DIAGNOSTICS

Referenzzentrum für Maligne Lymphome kommt in die Pathologie des USB

Prof. Dr. Stephan Dirnhofer

Die SAKK (Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung) unterhält ein Referenzzentrum zur histologischen Diagnostik von malignen Lymphomen (RZML). Seit 1998 war dieses am Institut für Pathologie des Kantonsspitals St. Gallen angesiedelt. Am 1. Januar 2019 wird das RZML nun nach Basel transferiert werden und unter der Leitung von Prof. Stephan Dirnhofer, Stv. Chefarzt am Institut für Medizinische Genetik und Pathologie des USB, stehen. Dieser Schritt soll sicherstellen, dass der immer wichtiger werdenden translationalen Forschung im Rahmen der klinischen Studien vonseiten der Pathologie besser entsprochen werden kann. Konkret bedeutet dies, dass für alle zukünftigen SAKK Lymphom-Studien der sogenannte «Central Pathology Review» (die zentrale Diagnoseüberprüfung) in der Pathologie des USB durch Prof. Dirnhofer durchgeführt wird, verbunden mit einem «biobanking» der Proben und – falls möglich – einem translationalen Forschungsprojekt. Neben dieser wichtigen Expertenfunktion in klinischen Studien wird das RZML auch eine nationale und internationale  Einrichtung zur konsiliarischen Beurteilung schwieriger hämatopathologischer Präparate sein. Dabei wird die ganze Bandbreite des Fachgebiets abgedeckt, das heisst neoplastische und nicht-neoplastische Erkrankungen des Knochenmarks, des Thymus, der Milz sowie nodale und extranodale Lymphoproliferationen.

22.11.2018 / HONORS AND AWARDS

SAKK/Astellas Award to Dr. David Müller

Dr. David Müller (middle) receives the prize from the chair Prof. Dr. Viviane Hess (left) and Dr. Oswaldo Mirantes (right) from Astellas.

We congratulate Dr. David Müller for receiving the SAKK/Astellas GU Oncology Award 2018. He received this prestigious award for his research in the field of urothelial cancer: Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus. Here, for the first time, David Müller and colleagues link BK polyomavirus NCCR rearrangements with oncogenic transformation in urothelial cancer in an immunosuppressed patient. Dr. Müller performed this multidisciplinary work as a PhD student in the Laboratory for Translational Uropathology Research in collaboration with the Institute of Forensic Medicine and the Department of Biomedicine. The Laboratory for Translational Uropathology Research is the new joint research laboratory of the Department of Urology and the Institute for Pathology of the University Hospital Basel and focuses on advancing our understanding of urogenital diseases by combining basic, translational and clinical research. For more information about this research, please contact PD Dr. Cyrill Rentsch or Prof. Dr. Lukas Bubendorf.

08.08.2018 / RESEARCH

Neuronal Mitochondrial Dysfunction Activates the Integrated Stress Response to Induce Fibroblast Growth Factor 21

Graphical abstract. From Restelli L et al., Cell Reports, Volume 24, ISSUE 6, P1407-1414.

Normal functioning of the cells that make up our body requires the coordinated interplay between its various organelles. In many cases, an impaired interorganellar communication will activate a stress response to ensure the survival of affected cells. The molecular mechanisms underlying this stress response in brain neurons have now been characterized in detail by Lisa Restelli and Björn Oettinghaus, two postdoctoral researchers from Prof. Stephan Frank`s group at our institute. As the researchers write in Cell Reports, impairments on the level of mitochondria - organelles widely known as the „cell`s powerhouses“ for their capacity to generate ATP - impact the function of neighboring, interacting organelles such as the endoplasmic reticulum. This impaired interorganellar communication results in the induction and secretion of fibroblast growth factor 21 (FGF21) by affected nerve cells. Remarkably, as demonstrated by the researchers, this cytokine is also induced in various models of neurodegenerative disorders, where it can be detected prior to neuronal cell death.  As chronic cell stress is an important component in the pathogenic cascade leading to neurodegeneration, FGF21 might potentially lend itself as a biomarker for the pre-symptomatic detection of respective diseases, including e.g. Alzheimer`s dementia and Parkinson`s disease. However, as FGF21 can also be produced by other tissues and organs, such as adipose tissue and liver, further rigorous testing will be required. On the other hand, the availability of a robust biomarker would undoubtedly represent an important advance in the development of novel approaches targeting chronic cell stress to provide neuroprotection. The study was realized in collaboration with partners at the universities of Cambridge (UK) and Padua (IT). For more information, please contact Prof. Dr. Stephan Frank.

22.6.2018 / RESEARCH

Genetic Predisposition to Medulloblastomas

Proposed guidelines for medulloblastoma patient genetic counseling and testing. From Waszak SM et al., Lancet Oncology.

Recent advances in molecular neuropathology have changed our perception of medulloblastoma (MB), the most common malignant brain tumor of childhood. Once considered a single tumor entity, it has now become clear that „medulloblastoma“ in fact subsumes various biologically and molecularly different tumors. This concept has also been adopted by the WHO, which currently distinguishes four main MB subgroups, of which MBs arising from alterations of the SHH- and WNT-signaling pathways are best understood. A multicenter study with participation of our institute, published this month in Lancet Oncology, reports on the actual contribution of cancer predisposition syndromes to MB. In this context, besides the “usual suspects” in this case, APC (MB-WNT), PTCH1 & SUFU1 (MB-SHH), and TP53, the study also identified germline mutations in BRCA2 and PALB2, both so far only known in the context of Fanconi anemia. In contrast to MB patients with tumors of the so-called subgroups 3 and 4 where damaging germline mutations were only rarely identified, about one fifth of MB-SHH tumors developed in the context of genetic predisposition. The study thus highlights the need for dedicated genetic counseling and screening programs dependent on clinical and molecular MB characteristics. For more information, please contact Prof. Dr. Stephan Frank.

06.04.2018 / DEVELOPMENT

First Identification of Diagnostically Relevant BRAF Gene Mutations With Potential Therapeutic Impact in Nodal Marginal Zone Lymphomas

Immunohistochemical staining of a nodal MZL biopsy with positive BRAF status (left). The detected BRAF mutations were located in the protein tyrosine kinase domain (right).

Two postdoctoral researchers (Dr. Vincent Pillonel and Dr. Darius Juskevicius) from the hematopathology research group of Prof. Alexandar Tzankov have recently published the results of their study “High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations” in the renowned journal Leukemia.  By application of an especially devoted Next-Generation sequencing (NGS) pipeline consisting of exome sequencing and a customized lymphoma gene panel, followed by in-silico meta-analysis, they succeeded to comprehensively characterize defects in genes and pathways that are driving oncogenesis in nodal marginal zone lymphoma (MZL), which is an orphan disease mainly defined by negative findings. They also identified genetic alterations differentiating nodal MZL from other closely related entities, such as splenic and extranodal MZL, lymphoplasmacytic and follicular lymphomas. Of particular importance is the detection of the theranostic (and in a proportion of cases clonal) BRAF V600E mutation in multiple nodal MZL cases. Until recently this mutation, among B-cell neoplasms, was thought to occur only in hairy cell leukemia and was diagnostic (and of therapeutic importance) for this entity. Here, for the first time, diagnostically useful, and potentially therapeutically relevant BRAF mutations were detected in nodal MZL. For more information about this research area and/or its diagnostic application, please contact Prof. Alexandar Tzankov.

03.04.2018 / RESEARCH

Identification of a Novel Tumor Suppressor: the Protein Histidine Phosphatase LHPP

Lower expression of LHPP in hepatocellular carcinoma correlates with worse overall survival. From nature.com.

A team of researchers, led by Prof. Michael N. Hall and Dr. Sravanth Hindupur from the Biozentrum, University of Basel, has discovered a new anti-cancer protein, called LHPP. In collaboration with several members of our institute (M. Matter, S. Piscuoglio, C. Ng, L. Quagliata and L. Terracciano) the function of this protein has been analyzed in detail. LHPP prevents the uncontrolled proliferation of liver cancer cells and is also suitable as a biomarker for the diagnosis and prognosis of liver cancer, as was reported in Nature.  Histidine phosphorylation is a poorly characterized post-translational modification of proteins. Analysis of murine and human liver cancer revealed that NME1 and NME2, the only known mammalian histidine kinases, were upregulated. Conversely, expression of the histidine phosphatase LHPP was downregulated in the tumor. Consistent with these observations, global histidine phosphorylation was significantly upregulated in the liver cancer and sustained hepatic expression of LHPP in a liver cancer mouse model reduced tumor burden. Furthermore, in patients with liver cancer, low expression of LHPP correlated with increased tumor severity and reduced overall survival. In conclusion, for the first time, a protein histidine phosphatase was described with a tumor suppressive function which may pave the way towards new strategies in the fight against cancer. For further details about this research topic, please contact Dr. Matthias Matter.

 

01.03.2018 / DIAGNOSTICS

Towards personalized medicine: Basel Institute of Pathology is the first Swiss institution to offer DNA methylation profiling for tumor diagnostics.

Capper et al.: DNA methylation-based classification of central nervous system tumours. From Nature.com.

Whereas epigenetic signatures have been recognized as important contributors to tumorigenesis a couple of years ago, this knowledge is currently being translated into routine molecular tumor diagnostics at an amazing speed. Today, the long-awaited DNA methylation-based brain tumor classifier finally saw the light of day as publication in Nature (Capper D et al.).  Using Illumina 850k chip technology, Stefan Pfister’s group at the DKFZ in Heidelberg spearheaded a comprehensive multi-center study, and the results have elevated brain tumor diagnostics to an unprecedented level of granularity. Having participated in the development of the DNA methylation brain tumor classifier, for which Basel was one of the five external validation centers, our neuropathologists, Dr. Jürgen Hench and Prof. Dr. Stephan Frank, started embracing this new technology almost one year ahead of the current publication. The overall experience gained from the analysis of more than 1100 brain tumors suggests that, in as many as 12% of the cases, methylation profiling leads to a more refined classification, and in some cases even to clinically relevant changes in diagnoses. With some 150 tumors analyzed with the help of medical geneticist Dr. Per Hofmann, Jürgen and Stephan are convinced of the transformative potential of this diagnostic approach, which has already started to find similar applications in the molecular workup of other tumor groups (carcinomas, sarcomas).  At present, Basel stands as the only center offering this approach for routine molecular tumor diagnostics in Switzerland. For more information about brain tumor diagnostics, please contact Prof. Dr. Stephan Frank.

 

01.08.2017 / HONORS AND AWARDS

Dr. Luca Quagliata Selected for New EORTC Leadership Program in Clinical Research

Dr. Luca Quagliata

Clinical research has become a complex science requiring multidisciplinary expertise not only in the field of medicine and oncology, but also in the intricate regulatory environment. New skills are required beyond the classical methodology of clinical research to allow the new generation of researchers to properly face the fast evolving economic and strategic challenges for health care. For these reasons, the European Organisation for Research and Treatment of Cancer (EORTC) has established a new program named: “Early Career Investigator Leadership Program”. The program will elapse over the next two years starting October 2017. It will be built and professionalized, specifically for the leadership training in partnership with McKinsey. The overall goal of the program is to support the development of selected individuals who will position at various levels within the EORTC organisation during the next years. EORTC groups have identified several promising individuals within their membership and 43 participants have been selected. Among those, Dr. Luca Quagliata has been chosen. This represents an important personal achievement for Dr. Quagliata as well as a recognition of the pivotal role of our Institute in the context of translational and clinical research.

01.05.2017 / DEVELOPMENT

Thermo Fisher Scientific establishes Institute of Pathology as a Center of Excellence Partner

Looking forward to a successful collaboration: Prof. Luigi Terracciano, Mark Stevenson (President of Life Sciences Solutions for Thermo Fisher Scientific), Prof. Markus Tolnay and Dr. Luca Quagliata (from left).

Thermo Fisher Scientific Inc. has signed a long-term collaborative agreement with the Institute of Pathology at University Hospital Basel to establish the leading institution as the first Center of Excellence under the Oncomine™ portfolio program, a new initiative designed to develop and refine next-generation sequencing (NGS)-based oncology research assays with the intent to eventually introduce them into the clinic as companion diagnostics. Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. As part of the agreement, both organizations will also collaborate to form global alliances and strategic partnerships with biopharma groups and others in an effort to accelerate oncology and immune-oncology trials. Additionally, the Institute of Pathology will serve as one of the Center of Excellence program’s global sites focused on conducting research and validation of Thermo Fisher’s Oncomine NGS portfolio of products.

21.02.2017 / HONORS AND AWARDS

SNF BioLink Grant to Pathology USB

The PathoLink Team at Pathology USB: Prof. Markus Tolnay, Dr. Serenella Eppenberger-Castori and Prof. Luigi Terracciano (from left).

The Swiss National Science Foundation launched the BioLink program for funding the networking of biobanks established for research purposes. BioLink is intended for investigators who wish to network their biobanks using IT systems. This harmonisation of the IT systems will result in the sharing of data so as to address well-defined, scientific questions. For the 2016 call, SNF supports three projects, one of which based at Pathology USB. In the project entitled "PathoLink: Connecting biobanks to determine mechanisms of metastasis formation" the five University based Institutes of Pathology are working in close collaboration together with the respective ICT units and the Swiss Institute of Bioinformatics. The project is aimed to foster translational cancer research within the framework of the Swiss Personalized Health Network.

01.02.2017 / DEVELOPMENT

New Custom Gene Panel for Molecular Diagnostics of Lymphoma

Four different ways of analyzing a lymphoma: By usage of A) immunohistochemistry; B) Fluorescence-In-Situ Hybridization; C) Sanger-Sequencing; D) Next-Generation-Sequencing (NGS) profiling.

The Research Unit of the Institute for Pathology is pleased that the laboratory department has integrated the lymphoma gene panel for next-generation sequencing (NGS) in its routine molecular diagnostic portfolio. This gene panel was developed by Dr. Darius Juskevicius as part of his PhD research project and was published last year in the journal Leukemia. It covers the 68 genes that are frequently mutated in B-cell lymphomas, such as MYD88, EZH2, PIM1, TP53, BCL2 or KMT2D. In 20 out of the 68 genes the targeted region covers all exons; in the remaining 48, specific exons or hotspots of the respective genes are selected. Detailed information about the genes and exons of this custom panel can be retrieved here. This new panel provides a useful tool for more accurate diagnosis of lymphoproliferative disorders and discloses potential genomic vulnerabilities that can be used for targeted personalized medicine approaches in patients with an advanced stage or relapsed disease. The rapid translation of the research findings to routine diagnostic application was possible due to the strong interaction of the research unit and the diagnostic laboratory department. Our research unit is composed of almost 30 researchers working in the two focal areas of translational cancer research and neurodegenerative diseases. We are dedicated towards developing novel diagnostic tools and assays based on the results of ours and other’s scientific investigations of underlying disease mechanisms. For more information about our research or diagnostic applications in lymphoma, please contact Prof. Dr. Alexander Tzankov (see article in UNI NOVA). For general inquiries about our research, PD Dr. Christian Ruiz.

26.09.2016 / HONORS AND AWARDS

First Poster Price of the SGU to Dr. David Müller

Dr. David Müller

We congratulate Dr. David Müller for winning the first poster prize of this year’s annual meeting of the Swiss Society of Urology (SGU). He received the award in the category of Basic Research for the work “Delineation of advanced prostate cancer evolution identifies chromothripsis as a polyclonal event selecting for FKBP4 as a driver of castration resistance”. Dr. Müller is a PhD student in the Uropathology research group of the Institute for Pathology and his research focuses on the genomic changes occurring due to androgen deprivation therapy in advanced prostate cancer. For more information about his research, please contact Dr. David Müller.

15.09.2016 / HONORS AND AWARDS

David Y Mason Award to Dr. Darius Juskevicius

Dr. Darius Juskevicius receives the David Y Mason Award glass sculpture from Prof. Dr. Stefan Dirnhofer.

The Research Unit of the Institute for Pathology is delighted that Dr. Darius Juskevicius, a postdoctoral fellow of the research group of Prof. Alexandar Tzankov, receives the David Y Mason Award. This prestigious prize is awarded every second year to support a promising research project of a young researcher in the field of hematopathology. Dr. Juskevicius receives this award for his research proposal entitled “Genetic profiling of Hodgkin- and Reed-Sternberg cells of classical Hodgkin lymphoma enriched from archival formalin-fixed and paraffin-embedded tissue”. The prize was awarded during the 18th Meeting of the European Association for Haematopathology [LINK:http://www.eahp2016.com] in Basel. For more information about this research project, please contact Dr. Darius Juskevicius.

16.08.2016 / HONORS AND AWARDS

SNSF Ambizione Grant to Dr. Salvatore Piscuoglio

Dr. Piscuoglio Salvatore

Dr. Piscuoglio, a current postdoctoral fellow in the research unit of the Institute for Pathology has been awarded a Swiss National Science Foundation (SNSF) Ambizione grant. This highly competitive grant is provided by the SNSF to promote scientific independence of high potential investigators working at Swiss universities. This grant will allow Dr. Piscuoglio to pursue a new line of research and to establish his own research group within our institute. Dr. Piscuoglio’s research interests are to understand the genetic underpinnings of solid tumors and to identify genetic aberrations that can be exploited either as diagnostic markers and/or therapeutic targets using next generation sequencing (NGS) technologies. In particular, in the funded project, Dr. Piscuoglio will characterize the long-non coding RNA landscape of triple negative breast cancers. For more information please contact Dr. Salvatore Piscuoglio.

10.08.2016 / HONORS AND AWARDS

Dora Seif Award to Prof. Dr. Luigi Terracciano

Prof. Dr. Luigi Terracciano

We congratulate Prof. Dr. Luigi Terracciano for receiving the prestigious Dora Seif Award. Dr. Terracciano is professor for experimental pathology and head of the molecular pathology unit. His research group investigates the development of liver diseases, in particular the molecular and genomic structure of hepatocellular carcinoma. The Dora Seif prize is awarded every second year for the best research work leading to advances in early diagnostics and therapy treatment for patients with cancer. This year, Prof. Dr. Luigi Terracciano and Prof. Dr. Markus Heim receive this award in equal parts for their joint excellent work of investigating the development, classification and treatment of liver cancer. In particular, the award committee highlighted the successful and internationally esteemed collaboration of both awardees. For more information, please see the dedicated news of the University of Basel or contact Prof. Dr. Luigi Terracciano.

20.06.2016 / HONORS AND AWARDS

Maurice Goldblatt Award to Prof. Dr. Lukas Bubendorf

Award ceremony at International Congress of Cytology in Yokohama.

Prof. Dr. Lukas Bubendorf, professor for stem cell pathology and research group leader at the Institute for Pathology, was awarded with the prestigious Maurice Goldblatt Award of the International Academy of Cytology (IAC). He received this award and the associated gold medal at the opening ceremony of the 19th International Congress of Cytology in Yokohama (Japan). The award committee highlighted his merits “[…] for his innovative efforts to develop, test and introduce novel and modern techniques for the clinical practice in all aspects of cytology; and for his wide range of achievements in research […]”. Dr. Bubendorf is a senior consultant pathologist at the Institute for Pathology and head of the cytology unit. His research focuses on lung and urogenital cancers, in particular on the analysis of the molecular and genomic evolution. For more information, please visit the dedicated web site of the IAC.

01.06.2016 / RESEARCH

Genomic Analyses of DLBCLs Identify Clonally-Unrelated Relapses

Professor Alexandar Tzankov and his colleague Dr. Darius Juskevicius from the Institute for Pathology report in the current online issue of the journal Leukemia their novel findings on genomic analysis of relapsing diffuse large B-cell lymphomas (DLBCL). For this study they investigated a retrospective cohort of 20 paired relapsing and 20 non-relapsing DLBCL patients by array-comparative genomic hybridization and targeted deep sequencing. The researchers discovered that 15% of the patients who were affected by DLBCL recurrences suffered from novel clonally-unrelated tumors and not from clonally-related outgrowths of the primaries. This finding raises a question of immadiate clinical impact, i.e. whether a standard first-line treatment might be (again) effective for these patients, thus avoiding the side effects of a more aggressive chemotherapy that is usually applied to treat relapsed DLBCL. Additionally, they discovered that truly clonally-related DLBCL relapses can be genetically either closely or distantly related to the respective primary tumors. These differences potentially reflect different mechanisms through which primary tumors overcome therapy and recur. For the genomic analyses of this study, the researchers developed a custom lymphoma sequencing gene panel that is now being validated for use in diagnostic routine. For more information, please access the publication or contact Prof. Dr. Alexandar Tzankov.

18.05.2016 / HONORS AND AWARDS

Rudolf-Virchow-Preis 2016 Awarded to Prof. Dr. Daniel Baumhoer

The Research Unit of the Institute of Pathology congratulates Prof. Dr. Daniel Baumhoer for winning the prestigious Rudolf-Virchow-Preis. It is awarded by the German Society of Pathology to honor his outstanding scientific work on DNA repair deficiency in osteosarcomas (so-called BRCAness) recently published in Nature Communications. Dr. Baumhoer is a senior consultant pathologist at the Institute of Pathology and head of the Bone Tumor Reference Center in Basel. His research group focuses on the molecular evolution of bone tumours and especially of osteosarcomas. For more information, please see the official press release or contact Prof. Dr. Daniel Baumhoer.

01.05.2016 / HONORS AND AWARDS

Research Fund of the University of Basel to Dr. Lisa Restelli

The Research Unit of the Institute for Pathology is delighted that Dr. Lisa Restelli, a postdoctoral fellow of the research group of Prof. Stephan Frank, has been selected as recipient of the research fund of the career advancement center of Basel University. These grants are awarded in order to promote the academic careers of outstanding junior researchers at the local university. Lisa Restelli has obtained her PhD in Neurobiology from the University of Basel, studying the role of mitochondria shape regulators in brain physiology and metabolism. She will now further pursue this aspect by exploring the role of mitochondrial morphology in selected disease paradigms, e.g. Parkinson’s disease. For more information about our research in neurodegeneration, please visit our dedicated web site or contact Prof. Dr. Stephan Frank.

01.04.2016 / DEVELOPMENT

Start of Liquid Biopsy Diagnostics

Scanning electron microscopy (SEM) of human blood cells; © Dr. M. Oeggerli, micronaut.ch

The research unit of the Institute for Pathology is pleased that the diagnostic department offers liquid biopsy genomics as diagnostic tests for cancer patients from 1st of April. Development and thorough validation of these tests was performed in the research unit of the Institute for Pathology in order to achieve highest accuracy, specificity and sensitivity. These assays are based on analysis of the circulating cell-free DNA (cfDNA) isolated from blood plasma by means of next-generation sequencing (NGS) and digital PCR. They specifically investigate the genomic profile of the patient’s tumor and presence of predictive mutations by using only a standard blood withdrawal. Our research unit continues on active developing of novel genomic assays for diagnostic routine, but does also apply these assays to samples from basic research as well as from clinical studies. For further information on cfDNA analysis in research, please contact Dr. Ivana Bratic Hench. For diagnostic cfDNA services, Dr. Luca Quagliata.

01.03.2016 / WELCOME!

Two Postdocs join the Institute for Pathology

The research unit of the Institute for Pathology is very pleased to welcome Dr. Charlotte Ng and Dr. Salvatore Piscuoglio as new research associates. Dr. Ng is a trained bioninformatician from the University of New South Wales (Australia) with a PhD from the University of Cambridge (UK). Dr. Piscuoglio graduated at the Federico II University in Naples (I) and obtained his PhD from the University of Basel. Both recently completed their postdoctoral fellowships at the Memorial Sloan Kettering Cancer Center in New York where they focused on the genomic analyses of solid tumor specimens and circulating cell-free tumor DNA (liquid biopsies) by next-generation sequencing. Their broad experience and know how in cancer genomics and data analysis complement the emphasis on genomics as the focal area of cancer research at our institute. The research unit of the Institute for Pathology now comprises 11 postdoctoral fellows and 10 PhD students. For more information about our research, please contact Dr. Christian Ruiz.

01.01.2016 / RESEARCH

Osteosarcoma Sequencing Project Identifies Novel BRCA Mutation Signatures

In the early December issue of Nature Communications, Prof. Dr. Daniel Baumhoer and his colleague Dr. Michal Kovac from the Institute for Pathology reported on their findings of exome sequenced osteosarcomas. These rare and aggressive tumours of bone are known to harbour complex karyotypes with abundant numerical and structural aberrations that differ significantly between individual tumours. They found osteosarcomas not only to represent polyclonal populations of tumour cells with up 16 distinct subclones per sample and identified 14 individual driver genes but importantly also detected a common genetic trait despite inter- and intratumoural heterogeneity. More than 80% of osteosarcomas exhibited a specific combination of single-base substitutions, LOH, or large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours. Preliminary experiments involving osteosarcoma cell lines furthermore demonstrated a significant reduction of cell viability following PARP-inhibitor treatment indicating the genetic findings to be functionally relevant. These findings might serve as a molecular basis for more individualized and targeted treatment approaches in osteosarcoma which are urgently needed. For more information, please access the » publication or contact Prof. Dr. Daniel Baumhoer.

01.12.2015 / LABORATORY

Novel Research Laboratory inaugurated

Due to an increased demand, the research unit of the Institute for Pathology has continued enlarging its research capacities. The recent inauguration of the novel general research laboratory increases the number of laboratory and office spaces by 10 and 18, respectively. With this latest addition, the Institute for Pathology provides 296 m2 of laboratory area dedicated to research. In addition, 66 m2 area serve as research offices. The laboratory space is now composed of two general research laboratories as well as eight specialized research laboratories, such as immunohistochemistry and genomics. For further information, please visit our » research web or contact Dr. Christian Ruiz.